Vancouver, British Columbia – (May 1st, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) would like to correct its news release dated on April 17th, 2019 announcing the approval of the application entitled “Development and clinical assessment of novel biomarker drugs targeting SSAT1 for detection and therapeutic monitoring of glioblastoma”, submitted to the Collaborative Health Research Projects funding opportunity. The application was Canadian Institutes of Health Research (CIHR) in partnership with the Natural Sciences and Engineering Research Council of Canada (NSERC) and in collaboration with the Social Sciences and Humanities Research Council (SSHRC). The correct funding amount is $750,000 and not $400,000 over 3 years. BioMark is the industrial partner on the grant.
“The company during the time of the announcement factored only the funds provided by CIHR and not the matching portion from Natural Sciences and Engineering Research Council of Canada (NSERC) says, Rashid Ahmed, President and CEO. We apologize for the error and BioMark again would like to acknowledge CIHR, NSERC and SSHRC for the funding.
Collaborative Health Research Projects (CHRP) is a joint initiative between the Canadian Institutes of Health Research (CIHR), the Natural Sciences and Engineering Research Council of Canada (NSERC) and the Social Sciences and Humanities Research Council of Canada (SSHRC). CHRP grants support focused, interdisciplinary, collaborative research projects involving any field of the natural sciences or engineering and any field of the health sciences.
Proposed research projects should be innovative, with a strong focus on knowledge translation, and lead to health benefits for Canadians, more effective health services and/or economic development in health-related areas.